热门资讯> 正文
施罗德从布里斯托尔收回抗癌药物候选权
2024-05-03 03:04
- Bristol-Myers Squibb (NYSE:BMY) has returned the rights to a preclinical cancer drug candidate, an SOS1 inhibitor, back to Schrodinger (NASDAQ:SDGR).
- Schrodinger noted that it delivered a development candidate, and Bristol had been conducting IND-enabling studies on it.
- The two companies began their collaboration in 2020, which included a $55M upfront payment from Bristol and up to $2.7B in milestones. An immunology target and a neurology target that are part of that agreement are not impacted.
- Part of the reason why Bristol (BMY) may have returned the candidate is that it gained an SOS1 inhibitor, MRTX0902, currently in phase 1, through its recent $4.8B acquisition of Mirati Therapeutics.
- SOS1 is a protein that regulates the ability of the KRAS gene to cycle through "on" and "off" stages. KRAS mutations are involved in about one-third of cancers.
More on Bristol Myers, Schrödinger
- Schrödinger, Inc. (SDGR) Q1 2024 Earnings Call Transcript
- Schrödinger, Inc. 2024 Q1 - Results - Earnings Call Presentation
- Bristol Myers Squibb: Tough Times Continue
- Schrodinger tumbles 8% on Q1 misses; drug discovery revenue plummets
- Schrödinger misses top-line and bottom-line estimates; initiates Q2 and reaffirms FY24 outlook
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
